Lung cancer international最新文献_第3页

Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases. 厄洛替尼治疗非小细胞肺癌后吉非替尼引起的肝毒性:8例临床病例回顾

Lung cancer international Pub Date : 2012-01-01 Epub Date: 2012-11-08 DOI: 10.1155/2012/354657

Yukihiro Yano, Yoshinobu Namba, Masahide Mori, Yukie Nakazawa, Ayumi Nashi, Shinichi Kagami, Manabu Niinaka, Tsutomu Yoneda, Hiromi Kimura, Toshihiko Yamaguchi, Soichiro Yokota

{"title":"Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases.","authors":"Yukihiro Yano, Yoshinobu Namba, Masahide Mori, Yukie Nakazawa, Ayumi Nashi, Shinichi Kagami, Manabu Niinaka, Tsutomu Yoneda, Hiromi Kimura, Toshihiko Yamaguchi, Soichiro Yokota","doi":"10.1155/2012/354657","DOIUrl":"https://doi.org/10.1155/2012/354657","url":null,"abstract":"Objective. Gefitinib often induces liver damage. A few reports have described that the subsequent administration of erlotinib was associated with less hepatotoxicity, but the safety and efficacy of this treatment are still not fully investigated. Therefore, we evaluated retrospectively the patients with erlotinib following gefitinib-induced hepatotoxicity. Methods and Patients. We retrospectively reviewed the medical records between December 2007 and March 2010. The patients were evaluated including the following information: age, gender, histology of lung cancer, performance status, smoking status, epidermal growth factor receptor (EGFR) mutation status, liver metastasis, viral hepatitis, alcoholic liver injury, clinical response, and hepatotoxicity due to EGFR tyrosine kinase inhibitors. Results. We identified 8 patients with erlotinib following gefitinib-induced hepatotoxicity. All achieved disease control by gefitinib. Hepatotoxicity was grades 2 and 3 in 3 and 5 patients, respectively. The median duration of treatment with gefitinib was 112.5 days and the median time to gefitinib-induced hepatotoxicity was 51.5 days. The median duration of treatment with erlotinib was 171.5 days. Grade 1 and 2 erlotinib-induced hepatotoxicity was observed in 2 and 1 patient, respectively. Conclusions. Erlotinib administration with careful monitoring is thought to be a good alternative strategy for patients who respond well to gefitinib treatment but experience hepatotoxicity. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2012 ","pages":"354657"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/354657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33959370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Preoperative Total Serum Cholesterol and Patients' Survival in Resected Nonsmall Cell Lung Cancer. 术前血清总胆固醇与非小细胞肺癌切除术患者生存率的关系。

Lung cancer international Pub Date : 2012-01-01 Epub Date: 2012-11-26 DOI: 10.1155/2012/463520

Masaki Tomita, Takanori Ayabe, Tetsuya Shimizu, Kunihide Nakamura

引用次数: 5

Against Lung Cancer Cells: To Be, or Not to Be, That Is the Problem. 对抗肺癌细胞:生存还是毁灭，这是一个问题。

Lung cancer international Pub Date : 2012-01-01 Epub Date: 2012-02-01 DOI: 10.1155/2012/659365

Naoko Okumura, Hitomi Yoshida, Yasuko Kitagishi, Yuri Nishimura, Shio Iseki, Satoru Matsuda

{"title":"Against Lung Cancer Cells: To Be, or Not to Be, That Is the Problem.","authors":"Naoko Okumura, Hitomi Yoshida, Yasuko Kitagishi, Yuri Nishimura, Shio Iseki, Satoru Matsuda","doi":"10.1155/2012/659365","DOIUrl":"https://doi.org/10.1155/2012/659365","url":null,"abstract":"Tobacco smoke and radioactive radon gas impose a high risk for lung cancer. The radon-derived ionizing radiation and some components of cigarette smoke induce oxidative stress by generating reactive oxygen species (ROS). Respiratory lung cells are subject to the ROS that causes DNA breaks, which subsequently bring about DNA mutagenesis and are intimately linked with carcinogenesis. The damaged cells by oxidative stress are often destroyed through the active apoptotic pathway. However, the ROS also perform critical signaling functions in stress responses, cell survival, and cell proliferation. Some molecules enhance radiation-induced tumor cell killing via the reduction in DNA repair levels. Hence the DNA repair levels may be a novel therapeutic modality in overcoming drug resistance in lung cancer. Either survival or apoptosis, which is determined by the balance between DNA damage and DNA repair levels, may lender the major problems in cancer therapy. The purpose of this paper is to take a closer look at risk factor and at therapy modulation factor in lung cancer relevant to the ROS. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2012 ","pages":"659365"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/659365","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34129109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. 与肺癌预测和预后相关的分子标志物。

Lung cancer international Pub Date : 2012-01-01 Epub Date: 2012-09-19 DOI: 10.1155/2012/729532

Alphy Rose-James, Sreelekha Tt

引用次数: 22

Cigarette Smoking and Lung Cancer: Pediatric Roots. 吸烟与肺癌:儿科根源。

Lung cancer international Pub Date : 2012-01-01 Epub Date: 2012-08-30 DOI: 10.1155/2012/790841

Norman Hymowitz

{"title":"Cigarette Smoking and Lung Cancer: Pediatric Roots.","authors":"Norman Hymowitz","doi":"10.1155/2012/790841","DOIUrl":"https://doi.org/10.1155/2012/790841","url":null,"abstract":"A vast array of data suggests that early age of smoking onset enhances the risk for development of lung cancer in adulthood. Initiation of smoking at a young age may influence the development of lung cancer because of its effect on duration of smoking. Early onset of smoking also may serve as an independent risk factor. It may increase the likelihood that smoking occurs during a critical period of development that enhances susceptibility to the adverse effects of cancer causing agents in cigarette smoke, thereby facilitating the initiation of the carcinogenic process. While evidence for the latter hypothesis derives from a variety of sources, definitive proof has proven elusive. Whether or not early age of smoking serves as an independent risk factor for lung carcinogenesis, the consensus of the public health community is that prevention of smoking onset at a young age and early cessation are keys to stemming the current lung cancer pandemic. Population approaches to tobacco prevention and control, such as measures contained in the World Health Organization Framework Convention Tobacco Control Treaty, offer the best opportunity, on the scale needed, to create a smoke-free world and bring an end to the pandemic of tobacco-related disease. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2012 ","pages":"790841"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/790841","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34129111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Aggressive Palliation in Extensive Stage Small Cell Lung Cancer, Practice Guidelines versus Clinical Practice: A Case Report and Review of the Literature. 广泛分期小细胞肺癌的积极姑息治疗，实践指南与临床实践:一个病例报告和文献回顾。

Lung cancer international Pub Date : 2011-01-01 Epub Date: 2011-05-15 DOI: 10.4061/2011/659807

Edward F Miles, Laura L Jacimore, John W Nelson

{"title":"Aggressive Palliation in Extensive Stage Small Cell Lung Cancer, Practice Guidelines versus Clinical Practice: A Case Report and Review of the Literature.","authors":"Edward F Miles, Laura L Jacimore, John W Nelson","doi":"10.4061/2011/659807","DOIUrl":"https://doi.org/10.4061/2011/659807","url":null,"abstract":"Small cell lung cancer (SCLC) constitutes approximately 16% of all primary lung cancers, with more than 35,000 new cases per year. Two-thirds of patients present with extensive stage disease (ES-SCLC) due to a tendency to metastasize early. Outcomes remain poor, with a median survival of approximately 10 months and a two-year overall survival of <10%. Current recommendations call for combination chemotherapy alone in patients without localized symptoms. Thoracic radiation therapy following a good clinical response is controversial. We report on a patient with ES-SCLC that had an excellent response to chemotherapy and underwent whole brain radiotherapy for a known brain metastasis and consolidative radiotherapy to the thorax. His latest follow-up demonstrates only a stable residual pulmonary nodule and no evidence of active metastatic disease. ES-SCLC is a relatively common presentation with a variable burden of metastatic disease. In the absence of randomized trials demonstrating the efficacy of thoracic radiation therapy, the community radiation oncologist is placed in a difficult position when addressing these patients, particularly those with otherwise good performance status and a good response to initial systemic chemotherapy. More research in this area is sorely needed to help guide treatment recommendations. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2011 ","pages":"659807"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4061/2011/659807","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33959368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy. 晚期非小细胞肺癌患者的预后因素:患者特征和化疗类型。

Lung cancer international Pub Date : 2011-01-01 Epub Date: 2010-12-05 DOI: 10.4061/2011/152125

Salah Abbasi, Ahmed Badheeb

引用次数: 32

An Atypical Presentation with Diagnostic Challenge of a Large Cell Neuroendocrine Cancer of Lung: A Case Report and Review of the Literature. 肺大细胞神经内分泌癌的非典型表现及诊断挑战:1例报告及文献复习。

Lung cancer international Pub Date : 2011-01-01 Epub Date: 2011-06-14 DOI: 10.4061/2011/912098

Pavan Kumar Bhamidipati, Amanda Ribbeck, Goldees Liaghati-Nasseri, Ramesh Kumar, Babu Paidipaty B, John Bartnik

{"title":"An Atypical Presentation with Diagnostic Challenge of a Large Cell Neuroendocrine Cancer of Lung: A Case Report and Review of the Literature.","authors":"Pavan Kumar Bhamidipati, Amanda Ribbeck, Goldees Liaghati-Nasseri, Ramesh Kumar, Babu Paidipaty B, John Bartnik","doi":"10.4061/2011/912098","DOIUrl":"https://doi.org/10.4061/2011/912098","url":null,"abstract":"Large-cell neuroendocrine carcinomas (LCNECs) are relatively rare and aggressive neoplasms of the lung with very poor prognosis. Even though they are included in the classification of nonsmall cell carcinomas, they have a biological behaviour and physiological response to treatment more like small cell carcinomas of lung. We report an atypical case presentation of LCNEC in a 51-year-old gentleman who presented with diffuse metastases to the thoracic and lumbar spine, brain, and liver, posing a diagnostic challenge. The primary small central lung tumor was in close proximity to major vessels, rendering a biopsy of the primary cancer challenging and nearly impossible. The final diagnosis was established through immunohistochemistry staining and examination of liver biopsy from a metastatic lesion. We also included a review of the current literature pertinent to LCNEC, as well as the important role of tumor markers plus immunohistochemistry profiles in determining the origin of unknown primary tumors in such difficult patient presentations. ","PeriodicalId":91139,"journal":{"name":"Lung cancer international","volume":"2011 ","pages":"912098"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4061/2011/912098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33959369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5